Aimovig نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

aimovig

novartis new zealand ltd - erenumab 140 mg/ml;   - solution for injection - 140 mg/ml - active: erenumab 140 mg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - aimovig is indicated for prophylaxis of migraine in adults.

Aimovig نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

aimovig

novartis new zealand ltd - erenumab 140 mg/ml;   - solution for injection - 140 mg/ml - active: erenumab 140 mg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - aimovig is indicated for prophylaxis of migraine in adults.

Elpida 140 MILLIGRAM/1 TABLET الأردن - الإنجليزية - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

elpida 140 milligram/1 tablet

شركة أدوية الحكمة - hikma pharmaceuticals - dasatinib 140 milligram/1 tablet - 140 milligram/1 tablet

Meropenem Kabi 1140 MILLIGRAM/1 VIAL الأردن - الإنجليزية - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

meropenem kabi 1140 milligram/1 vial

مستودع أدوية الغروب - sun set drug store - meropenem trihydrate 1140 milligram/1 vial - 1140 milligram/1 vial

Zed 140.480 MILLIGRAM الأردن - الإنجليزية - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

zed 140.480 milligram

مستودع أدوية النور - noor drug store - sildenafil citrate 140.480 milligram - 140.480 milligram

Dasatinib Dar Al-Dawa 140 MG/1 TAB الأردن - الإنجليزية - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

dasatinib dar al-dawa 140 mg/1 tab

شركة دار الدواء للتنمية والأستثمار - dar al dawa development and investment co ltd - dasatinib 140 mg/1 tab - 140 mg/1 tab

NAPROXEN tablet, delayed release الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

naproxen tablet, delayed release

remedyrepack inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen delayed-release tablets are indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis naproxen delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [ see warnings and precautions (5.7, 5.8) ]. - in the setting of coronary artery bypass graft (cabg) surgery [ see warnings and precautions ( 5.1) ]. risk summary use of nsaids, including naproxen delayed-release tablets, duri